StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck isentress / Isentress HD (raltegravir — HIV-1 integrase inhibitor) — U.S. sales ($M) ($M)

Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b

Latest, FY2025
181
Period ended Dec 31, 2025
Change on a year earlier
-2.2%
185 in FY2024
History
10 years
Since FY2016
Sources
9
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedIsentress / Isentress HD (raltegravir — HIV-1 integrase inhibitor) — U.S. sales ($M) ($M)Year on yearSource
FY2025Dec 31, 2025181-2.2%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
FY2024Dec 31, 2024185-14.0%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
FY2023Dec 31, 2023215-21.5%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
FY2022Dec 31, 2022274-6.8%Form 10-K (filed 2025-02-25) ↗
FY2021Dec 31, 2021294-9.8%Form 10-K (filed 2024-02-26) ↗
FY2020Dec 31, 2020326-18.1%Form 10-K (filed 2023-02-24) ↗
FY2019Dec 31, 2019398-22.4%Form 10-K (filed 2022-02-25) ↗
FY2018Dec 31, 2018513-9.2%Form 10-K (filed 2021-02-25) ↗
FY2017Dec 31, 2017565-21.6%Form 10-K (filed 2020-02-26) ↗
FY2016Dec 31, 2016721–Form 10-K (filed 2019-02-27) ↗

Breakdown

What makes up isentress / isentress hd (raltegravir — hiv-1 integrase inhibitor) — u.s. sales ($m)

Cite this data

StockData. (2026). Merck Isentress / Isentress HD (raltegravir — HIV-1 integrase inhibitor) — U.S. sales ($M) ($M), annual FY2016–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_isentress_us

See every metric in the Merck KPI table. Data updated Oct 26, 2026.